Collegium Pharmaceutical/$COLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Ticker
$COLL
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
357
ISIN
US19459J1043
Website
COLL Metrics
BasicAdvanced
$993M
24.68
$1.25
0.63
-
Price and volume
Market cap
$993M
Beta
0.63
52-week high
$39.84
52-week low
$23.23
Average daily volume
279K
Financial strength
Current ratio
1.206
Quick ratio
1.013
Long term debt to equity
411.943
Total debt to equity
411.943
Interest coverage (TTM)
2.25%
Profitability
EBITDA (TTM)
364.824
Gross margin (TTM)
87.04%
Net profit margin (TTM)
6.61%
Operating margin (TTM)
26.27%
Effective tax rate (TTM)
32.54%
Revenue per employee (TTM)
$1,860,000
Management effectiveness
Return on assets (TTM)
7.95%
Return on equity (TTM)
19.23%
Valuation
Price to earnings (TTM)
24.675
Price to revenue (TTM)
1.495
Price to book
4.24
Price to tangible book (TTM)
-1.32
Price to free cash flow (TTM)
5.053
Free cash flow yield (TTM)
19.79%
Free cash flow per share (TTM)
611.56%
Growth
Revenue change (TTM)
17.17%
Earnings per share change (TTM)
-45.82%
3-year revenue growth (CAGR)
34.52%
3-year earnings per share growth (CAGR)
2.00%
10-year earnings per share growth (CAGR)
-20.74%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
Bulls say / Bears say
Collegium Pharmaceutical reported record net revenue of $159.3 million in Q3 2024, a 17% year-over-year increase, driven by strong sales of Belbuca and Xtampza ER. (biospace.com)
The acquisition of Ironshore Therapeutics introduced Jornay PM to Collegium's portfolio, expanding its presence into the neurology market and diversifying revenue streams. (pharmaceutical-technology.com)
Jefferies upgraded Collegium's stock from Hold to Buy, citing undervaluation and strong financial performance, with a new price target of $44.00. (investing.com)
The entry of generic competitors for Belbuca could erode market share and pricing power, potentially impacting Collegium's revenue growth and profitability. (monexa.ai)
Insider selling activity, such as EVP Thomas B. Smith selling 9,593 shares, might signal concerns about the company's future performance among executives. (techdows.com)
The integration of Ironshore Therapeutics and the commercialization of Jornay PM may present operational challenges and require significant resources, potentially affecting short-term profitability. (pharmaceutical-technology.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
COLL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Collegium Pharmaceutical stock?
Collegium Pharmaceutical (COLL) has a market cap of $993M as of July 08, 2025.
What is the P/E ratio for Collegium Pharmaceutical stock?
The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 24.68 as of July 08, 2025.
Does Collegium Pharmaceutical stock pay dividends?
No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Collegium Pharmaceutical dividend payment date?
Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.
What is the beta indicator for Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.